Clinical Trial Update: PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer [Phase 3]

View source ↗

Summary

A phase 3 trial is evaluating a PD-1 inhibitor in combination with chemotherapy, with or without radiotherapy, for metastatic esophageal cancer; recruitment is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• PD-1 inhibitor (unspecified)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Esophageal Neoplasms | Phase 3 | Status: RECRUITING